|
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical research trials and A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus  A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
For Condition: Diabetes
Status: No longer recruiting
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 2 to 5 mg/day will be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 35 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 35 to 75 - Type 2 diabetes for longer than 3 months - HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening - FPG (fasting plasma glucose) greater than 126 mg/dL at screening - BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: - Type I diabetes - Type 2 diabetes patients currently treated with insulin - Type 2 diabetes patients curently or previously treated with Actos, Avandia ot Rezulin - FPG (fasting plasma glucose) greater than 270 mg/dL at baseline - Impaired liver or kidney function - Triglycerides greater than 600 mg/dL - Uncontrolled hypertension - Pregnant or lactating women - Women not using adequate contraception
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: BM17151;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057304
Other Diabetes Studies:
1. A Multicenter Study to Evaluate Retisert in the Treatment of Patients with Diabetic Macular Edema
2. Family-Centered Diabetes Project
3. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
4. Differential Metabolism of Dietary Fatty Acids
5. Prevalence of carbohydrate intolerance in lean and obese children
Related Studies:
Other Diabetes Clinical Trials
Other Oregon Clinical Trials
Other Portland Clinical Trials
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
